2cureX announced the extension of the IndiTreat® distribution agreement with Werfen. Under the terms of this extension, Werfen's distribution territory now includes Spain, Portugal and Andorra. The agreement with the previous distributor, Lab52, has been terminated.

With a population of more than 10 million people and 10,500 new colorectal cancer patients every year, Portugal is a very important market for 2cureX. Its public healthcare system (Serviço Nacional de Saúde, SNS) is organized in eight health regions and has approximately 40 hospitals.